CureFAKtor Pharmaceuticals. LLC Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor Disrupts FAK-VEGFR3 Interaction and Inhibits Pancreatic Tumor Growth
4/3/2012 11:00:36 AM
More...
|
CureFAKtor Pharmaceuticals. LLC Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor Y15 Decreased Glioblastoma Tumor Growth & Increased Lung & Colon Cancer Cell Death
11/14/2011 1:49:31 PM
More...
|
CureFAKtor Pharmaceuticals. LLC Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
11/14/2011 1:15:52 PM
More...
|
CureFAKtor Pharmaceuticals. LLC to Present at 10th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/19/2011 11:24:31 AM
More...
|
CureFAKtor Pharmaceuticals. LLC Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
6/23/2011 9:15:04 AM
More...
|
CureFAKtor Pharmaceuticals. LLC Featured at University of Florida Innovation Showcase 2011
4/19/2011 7:23:18 AM
More...
|
CureFAKtor Pharmaceuticals. LLC Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
1/21/2011 6:31:43 AM
More...
|
CureFAKtor Pharmaceuticals. LLC Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
1/18/2011 10:28:36 AM
More...
|